Best Practice Intravitreal injections in a safe and sustainable way

Author: Project Group Sustainable Ophthalmology, Redmer van Leeuwen

Approved by the Working Group on Medical Retina and chair of the Quality Committee of the Dutch Ophthalmology Society, March 2021

Final version, approved by the Medical Retina working group

1. Introduction

2. What do the current guidelines say?

3. Advice

4. Conclusion

5. Worked out example

6. References

7. Figure

1. Introduction
The injection of medication into the vitreous humor of the eye, the intravitreal injection (IVI), was developed in 2003, later the number of injections has exploded worldwide. In the Netherlands, the number of IVIs has increased from 100,000 injections in 2012 to 300,000 injections in 2019 (NZa figures). For the time being, there seems to be no alternative for this successful labour-intensive therapy.

The first guideline for the IVI procedure in 2004 (Aiello, 2004), which was revised in 2014 (Avery, 2014). In Dutch practice, this guideline appears to have been worked out well in essence. There does appear to be a diversity in the materials used (see Figure 1).

1 Introduction

The main complications of an IVI are endophthalmitis, lens perforation, corneal erosion, and conjunctival hemorrhage. Endophthalmitis is the most serious complication and has an incidence of 0.01 – 0.26% (Menchini, 2018). An IVI guideline should aim to prevent this complication. This requires optimal disinfection of the eye and rapid and sterile introduction of the needle into the eye.

The aim of this Best Practice is to advise on how ophthalmologists in the Netherlands can perform the IVIs as safely and sustainably as possible. Not using unnecessary materials has the most impact on sustainability, fully through reuse and finally recycling waste from (reduce-reuse-recycle principle). Given the enormous quantities, a small saving per procedure can lead to significant gains in terms of costs, waste, and carbon footprint (see point 5). Therefore, the aim should be to use only the essential parts with an IVI and to leave unnecessary gestures.
2. What do the current Guidelines say?

This Best Practice is based on the 'Updated Guidelines of an Expert Panel' from the US (Avery 2014, see Figure 2), the 'Euretina Expert Consensus Recommendations' from 2018 (Gryzbowski 2018, see Figure 3) and the Dutch guideline AMD from 2014. In these recommendations by American and European experts, all steps of the IVI procedure are substantiated with the most recent scientific literature and the opinion of retina experts. The text below quotes from these recommendations. In exceptional cases, references are made to specific publications. Sometimes reference is made to other guidelines or literature.

**Setting/Space**

The legal requirements in this regard differ between countries and so does clinical practice. In the US and Canada, most IVIs are performed in the doctor's office, while in other countries the OR or treatment room is used. The question is this difference is reflected in the risk of endophthalmitis. Studies in the US report incidence rates of 0.029% to 0.057%. In countries where the IVI takes place in the OR, an incidence of 0.009% to 0.021% is found. Comparative studies could not find any difference in risk between office-based and OR-based procedures. The effect of air control was also not demonstrable (Dossarps 2015).

Euretina expert panel: “In conclusion, operating theatre, adequate room or in-office settings are recommended for IVI.”

**Anesthetics**

Usually proparacaine or lidocaine drops are used. There is no evidence for superiority of any particular type of anesthetic. The added value of a cotton swab soaked in anesthetic has also not been demonstrated. A retrospective analysis of a US clinic found that the use of lidocaine gel was associated with an increased risk of endophthalmitis (Stern et al 2019).
Topicale antisepsis

It is recommended by both guidelines to disinfect the fornix and conjunctiva with povidone iodine eye drops, preferably 2 times, and leave on for 30 seconds. Usually the 5% concentration is used. Brushing the eyelids is not recommended because this can release bacteria from the meibomian glands. Dropping povidone iodine on the eyelids is recommended by some. Chlorhexidine is a safe alternative.

Perioperative antibiotics

A systematic review and meta-analysis showed that antibiotic prophylaxis is not associated with a reduction in endotalmitis risk (Benoist d'Azy et al, 2016). Also, a recent large study from Japan showed again that topical antibiotic prophylaxis does not reduce the risk of endophthalmitis (Morioka et al 2020). Unnecessary use of antibiotics will lead to resistance. For this reason, the use of antibiotic drops is not recommended, both before and after the IVI procedure.

Pupil dilation

In some countries, ophthalmologists want the pupil to be dilated to allow visualization of the lens and papilla. However, this is not essential and is not recommended as standard procedure. Informing the patient about light perception is a good alternative.

Injection location

There is agreement on the location of the injection: 3.5 to 4 mm from the limbus. In the US, only 56% of respondents measured this distance for the IVI, mostly using a marker. No statement is made about the necessity of using a compass or marker.

Eyelid spreader

The usefulness of an eyelid dilator has been demonstrated in a prospective, placebo-controlled trial with pegabtabnib, in the early years of the IVIs (Mansour et al 2012). Alternatives have been studied, but there seems to be a consensus about the standard use of an eyelid dilator in IVIs. No statement is made about the type of spreader or the choice between reusable or disposable spreader.

Gloves, clothing, and drapes
The WHO prescribes the use of surgical gloves in surgical interventions in general (WHO guidelines on hand hygiene in health care, 2009). There are no prospective randomized studies on the use of sterile or non-sterile gloves or drape in an IVI.

The US expert panel (Avery 2014) stated that the use of sterile or non-sterile gloves fits into modern clinical practice, in combination with hand washing. In addition, these experts argued that the use of a sterile drape is optional. Applying a hole cloth to the face can cause stress and discomfort, takes time, and was found to even lead to more infections in a Cochrane review of 5 randomized trials (Tailor 2011; Webster 2013). For this reason, it seems better not to use a drape.

US expert panel: “Although the use of gloves has not been shown to reduce the risk of endophthalmitis, sterile or nonsterile gloves may be used as consistent with modern office practice. There is no evidence to support the routine use of a drape when performing IVT injections.”

Euretina expert panel: “In summary, there is no significant evidence that the use of sterile gloves or drape reduces endophthalmitis rates or adverse events, as prospective and randomized controlled trials are lacking. From the available data we conclude to consider gloves, sterile or nonsterile, appropriate for IVI; draping, however, may not be essential. Appropriate clothing depending on the IVI setting is advised.”

**Face mask**

Several studies have shown that wearing a mask as well as being silent by the surgeon significantly reduces the spread of bacteria from the oral flora. It is therefore recommended that the doctor and nurse wear a mask during the IVI procedure. Recently, through experimental research has shown that wearing a mouth mask by the patient can actually increase the risk of endophthalmitis (Hadayer et al, 2020).

No statement is made about hat and jacket, but there seems to be no hard indication to recommend this personal protection in this setting.

**Eye bandage/eye pad**

In the guidelines of the American and European experts, no statement is made about an eye bandage after the IVI. There doesn't seem to be any medical argument for this either. The wound is closed and does not leak. Patient comfort could well be an argument.
3. Advice

Based on the above, the following advice applies to the requirements for an IVI:

**Essential:**
Mouth mask (operator and assistant)
Gloves (sterile or non-sterile, operator only)
Anesthetic eye drops
Povidone iodine drops
Sterile eyelid spreader (single use or reusable)

**Optional:**
Compass/marker (preferably reusable)
Cotton swabs for iodine fornix
Non-sterile gauze and non-sterile fluid for removing iodine
Eye ointment (usable for several patients)

**Not necessary:**
Hole cloth
Swab for anesthesia and massage
Tweezers
Hat
Jacket (for doctor and patient)
Tablecloth

Antibiotics Pre and Post Injection

Savings can be made by omitting optional and unnecessary parts (Reduce). An option that needs further investigation is the reuse of gloves (Reuse), for example by washing the hands with alcohol while wearing gloves between procedures.

**Tips:**
- Use a non-sterile tray of iodine for multiple patients
- Iodine can also be poured into the packaging/bag of the cotton swabs, instead of in a container
- Bottles of oxy/tetracaine/cocaine instead of minims
- Use sterile (crepe) paper wrapping paper, instead of plastic coated paper

4. Conclusion
In order to realize savings in costs, waste and CO2 emissions, it makes sense to critically assess the material you are currently using for the IVI and to adjust it if necessary. This Best Practice, based on the literature, can help with that.

Given the large numbers of IVIs, the use of only essential materials during this procedure leads to significant savings in costs, waste and CO2 emissions. Based on this Best Practice, based on the literature, you can critically assess your IVI procedure: you can omit optional and unnecessary parts. Finally, the choice of materials from which the IVI set is built can also contribute to a saving in costs and CO2 emissions.

5. Saving example

In the UMC Utrecht, a disposable IVI set has been used for many years with a plasticized tablecloth, metal spreader, 2 plastic swabs for iodination of the fornix, 1 plastic swab for anaesthesia, a plastic measuring stick, a container for the iodine, and a plastic container. for the sturdiness. All together this set weighs 135.5 grams. This IVI set was adapted on the basis of the above Best Practice. After removing the two plastic containers, replacing the plasticized tablecloth with a much smaller crepe paper sheet, and a much smaller packaging, this weight had decreased to 66.5 grams. In combination with recycling of the clean paper and plastic, a reduction in the carbon footprint from 0.68 kilograms of CO2 to 0.17 kilograms of CO2 could be achieved. See Figure 4 for the exact dates. If this reduction of 75% is extended to the 300,000 injections that take place annually in the Netherlands, based on approximately identical disposable IVI sets, a gain of 153,000 kg CO2 is possible. This carbon footprint corresponds to 695,461 kilometers of driving.

References


- Avery et al, Intravitreal injection technique and monitoring. Updated guidelines of an expert panel. Retina 34:S1-S18, 2014


- Hadayer et al. Patients wearing face masks during intravitreal injections may be at a higher risk of endophthalmitis. Retina 40(9):1651-1656, 2020


- Nederlandse Zorgautoriteit https://www.opendisdata.nl/msz/zorgactiviteit/039810

- WHO guidelines on hand hygiene in health care 2009 https://apps.who.int/iris/bitstream/handle/10665/44102/9789241597906_eng.pdf?sequence=1&isAllowed=y&ua=1


Figuur 1. Various IVI sets in the Netherlands.

8

Table 2. Areas of General Agreement by Committee Members

<table>
<thead>
<tr>
<th>Area of Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Povidone–iodine (5–10%) should be the last agent applied to the intended injection site before injection. If a gel anesthetic is used, povidone–iodine should be applied both before and after application of gel, as retained gel may prevent povidone–iodine from contacting the conjunctival surface of the injection site.</td>
</tr>
<tr>
<td>Pre-, peri-, or postinjection topical antibiotics are unnecessary.</td>
</tr>
<tr>
<td>There is no evidence to support the routine use of a sterile drape.</td>
</tr>
<tr>
<td>Avoid contamination of the needle and injection site by the eyelashes or the eyelid margins.</td>
</tr>
<tr>
<td>Avoid extensive massage of the eyelids either pre- or postinjection (to avoid meibomian gland expression).</td>
</tr>
<tr>
<td>Use adequate anesthetic for a given patient (topical drops, gel, and/or subconjunctival injection).</td>
</tr>
<tr>
<td>Use of sterile or nonsterile gloves as consistent with modern office practice, combined with strong agreement regarding the need for handwashing before and after patient contact.</td>
</tr>
<tr>
<td>Either surgical masks should be used or both the patient and providers should minimize speaking during the injection preparation and procedure to limit aerosolized droplets containing oral contaminants from the patient and/or provider.</td>
</tr>
<tr>
<td>Monitor IOP both pre- and postinjection.</td>
</tr>
<tr>
<td>Routine anterior chamber paracentesis is not recommended.</td>
</tr>
</tbody>
</table>

Table 3. Areas With No Clear Consensus by Committee Members

<table>
<thead>
<tr>
<th>Area of Disagreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Need for povidone–iodine application to the eyelids, including the eyelashes and eyelid margins. All agreed that when povidone–iodine is applied to the eyelashes and eyelid margins, eyelid scrubbing or eyelid pressure adequate to express material from the meibomian glands should be avoided.</td>
</tr>
<tr>
<td>Use of a speculum (some prevent contact between the needle/injection site and the eyelashes and eyelids with manual lid retraction).</td>
</tr>
<tr>
<td>Need for pupillary dilation and postinjection dilated examination of the posterior segment (although some viewed the return of formed vision as sufficient, others routinely dilate the pupil and examine the posterior segment after injection).</td>
</tr>
<tr>
<td>Use of povidone–iodine flush (most preferred drops only and saw no benefit to allowing the povidone–iodine to dry before injection).</td>
</tr>
</tbody>
</table>
**Figuur 2. From Avery et al., 2014**

**Table 1. Expert consensus recommendations on intravitreal injections (IVI)**

<table>
<thead>
<tr>
<th>Subject</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical setting for IVI</td>
<td>Operating theater, adequate room or in-office setting</td>
</tr>
<tr>
<td>Anesthetics</td>
<td>Topical anesthesia</td>
</tr>
<tr>
<td></td>
<td>No recommendation for a specific substance or technique</td>
</tr>
<tr>
<td>Topical antisepsis</td>
<td>Topical administrations of 5% povidone-iodine over at least 30 s into the conjunctival sac. Chlorhexidine for patients with local irritation due to povidone-iodine</td>
</tr>
<tr>
<td>Perioperative antibiotics</td>
<td>Not recommended</td>
</tr>
<tr>
<td>Pupil dilation</td>
<td>No concluding recommendation, but it might be advisable for beginners in order to be able to immediately examine the retinal vessel perfusion after IVI</td>
</tr>
<tr>
<td>Globe softening</td>
<td>No recommendation</td>
</tr>
<tr>
<td></td>
<td>Might be considered in vulnerable eyes</td>
</tr>
<tr>
<td>Lid speculum</td>
<td>Sterile speculum is recommended</td>
</tr>
<tr>
<td>Needle gauge and length</td>
<td>30-gauge or thinner needles are recommended for liquid injections whereas larger needles should be used when necessary</td>
</tr>
<tr>
<td>Injection location</td>
<td>Inject through the pars plana, between 3.5 and 4 mm from the limbus Switch injection sites if patients receive repeated IVI</td>
</tr>
<tr>
<td>Feasibility of bilateral injections</td>
<td>Handle each injection as separate procedure</td>
</tr>
<tr>
<td>Gloves/draping</td>
<td>Gloves are recommended</td>
</tr>
<tr>
<td></td>
<td>Draping may not be essential</td>
</tr>
<tr>
<td>Use of facial masks</td>
<td>Face masks recommended</td>
</tr>
</tbody>
</table>

**Figuur 3. From Grzybowski et al, 2018**

10
Figuur 4. Waste from disposable intravitreal sets at UMC Utrecht, broken down by weight of total waste, residual waste (hospital specific waste) and CO2 emissions.

<table>
<thead>
<tr>
<th></th>
<th>Totaal afval</th>
<th>Restafval</th>
<th>CO₂ footprint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>135,5 g</td>
<td>135,5 g</td>
<td>0,68 kg CO₂</td>
</tr>
<tr>
<td>Na reductie en reuse</td>
<td>66,5 g</td>
<td>66,5 g</td>
<td>0,36 kg CO₂</td>
</tr>
<tr>
<td>Na recycle</td>
<td>66,5 g</td>
<td>34,5 g</td>
<td>0,17 kg CO₂</td>
</tr>
<tr>
<td>Afname per injectie</td>
<td>69 g (-50,9%)</td>
<td>101 g (-74,5%)</td>
<td>0,51 kg CO₂ (-75%)</td>
</tr>
<tr>
<td>Afname per 50 injecties</td>
<td>3,45 kg</td>
<td>5,05 kg</td>
<td>25,5 kg CO₂</td>
</tr>
<tr>
<td>Afname per 300.000 injecties</td>
<td>20.700 kg</td>
<td>30.300 kg</td>
<td>153.000 kg CO₂</td>
</tr>
</tbody>
</table>

*